Premium
Inhibition of A23187–induced release of leukotriene B 4 in mouse whole blood Ex vivo and human polymorphonuclear cells in vitro by the cannabinoid analgesic cannabidiol
Author(s) -
Formukong E. A.,
Evans A. T.,
Evans F. J.,
Garland L. G.
Publication year - 1991
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.2650050606
Subject(s) - cannabidiol , ex vivo , cannabinoid , pharmacology , leukotriene , chemistry , in vivo , arachidonate 5 lipoxygenase , lipoxygenase , stimulation , in vitro , leukotriene b4 , immunology , biology , medicine , endocrinology , inflammation , biochemistry , arachidonic acid , enzyme , cannabis , receptor , microbiology and biotechnology , psychiatry , asthma
The effects of CBD, a potent analgesic cannabinoid on LTB 4 and TXB 2 production stimulated by A23187 was determined in mouse blood ex vivo and in human polymorphonuclear cells in vitro . At a dose of 10 mg/kg administered orally CBD inhibited LTB 4 production in mouse blood and was equieffective to the dual lipoxygenase/cyclo‐oxygenase inhibitor BW755C and the lipoxygenase inhibitor BWA4C used at a dose of 50 mg/kg. In the same blood samples CBD stimulated TXB 2 production from between 20 to 30% over a 4 h period. A23187 stimulation of LTB 4 synthesis in human polymorphonuclear cells was inhibited by CBD and Δ'‐THC in a dose related manner (IC 50 5.4 and 8.2 μm respectively). However, only CBD produced a 100% inhibition of LTB 4 synthesis. The production of TXB 2 in these cells was initially stimulated at low doses by CBD but at higher doses TXB 2 synthesis was inhibited.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom